drugset / Press release
European Medicines Agency Validates Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma
2021-10-04 · Ono Pharmaceutical Co., Ltd. · original ono-pharma.com ↗
This material is intended to notify the press release issued on October 1 (local time) by Bristol Myers Squibb, our license partner for Opdivo. Please click https://www.bms.com/media/press-releases.html for the original press release.
The release as fetched from its publisher. ono-pharma.com ↗